Literature DB >> 21840419

Influence of C-terminal α-helix hydrophobicity and aromatic amino acid content on apolipoprotein A-I functionality.

Nicholas N Lyssenko1, Mami Hata, Padmaja Dhanasekaran, Margaret Nickel, David Nguyen, Palaniappan Sevugan Chetty, Hiroyuki Saito, Sissel Lund-Katz, Michael C Phillips.   

Abstract

The apoA-I molecule adopts a two-domain tertiary structure and the properties of these domains modulate the ability to form HDL particles. Thus, human apoA-I differs from mouse apoA-I in that it can form smaller HDL particles; the C-terminal α-helix is important in this process and human apoA-I is unusual in containing aromatic amino acids in the non-polar face of this amphipathic α-helix. To understand the influence of these aromatic amino acids and the associated high hydrophobicity, apoA-I variants were engineered in which aliphatic amino acids were substituted with or without causing a decrease in overall hydrophobicity. The variants human apoA-I (F225L/F229A/Y236A) and apoA-I (F225L/F229L/A232L/Y236L) were compared to wild-type (WT) apoA-I for their abilities to (1) solubilize phospholipid vesicles and form HDL particles of different sizes, and (2) mediate cellular cholesterol efflux and create nascent HDL particles via ABCA1. The loss of aromatic residues and concomitant decrease in hydrophobicity in apoA-I (F225L/F229A/Y236A) has no effect on protein stability, but reduces by a factor of about three the catalytic efficiencies (V(max)/K(m)) of vesicle solubilization and cholesterol efflux; also, relatively large HDL particles are formed. With apoA-I (F225L/F229L/A232L/Y236L) where the hydrophobicity is restored by the presence of only leucine residues in the helix non-polar face, the catalytic efficiencies of vesicle solubilization and cholesterol efflux are similar to those of WT apoA-I; this variant forms smaller HDL particles. Overall, the results show that the hydrophobicity of the non-polar face of the C-terminal amphipathic α-helix plays a critical role in determining apoA-I functionality but aromatic amino acids are not required. This article is part of a Special Issue entitled Advances in High Density Lipoprotein Formation and Metabolism: A Tribute to John F. Oram (1945-2010). Copyright Â
© 2011 Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21840419      PMCID: PMC3227795          DOI: 10.1016/j.bbalip.2011.07.020

Source DB:  PubMed          Journal:  Biochim Biophys Acta        ISSN: 0006-3002


  52 in total

1.  Influence of apolipoprotein A-I domain structure on macrophage reverse cholesterol transport in mice.

Authors:  Eric T Alexander; Charulatha Vedhachalam; Sandhya Sankaranarayanan; Margarita de la Llera-Moya; George H Rothblat; Daniel J Rader; Michael C Phillips
Journal:  Arterioscler Thromb Vasc Biol       Date:  2010-11-11       Impact factor: 8.311

2.  Effects of increasing hydrophobicity on the physical-chemical and biological properties of a class A amphipathic helical peptide.

Authors:  G Datta; M Chaddha; S Hama; M Navab; A M Fogelman; D W Garber; V K Mishra; R M Epand; R F Epand; S Lund-Katz; M C Phillips; J P Segrest; G M Anantharamaiah
Journal:  J Lipid Res       Date:  2001-07       Impact factor: 5.922

3.  Influence of N-terminal helix bundle stability on the lipid-binding properties of human apolipoprotein A-I.

Authors:  Masafumi Tanaka; Padmaja Dhanasekaran; David Nguyen; Margaret Nickel; Yuki Takechi; Sissel Lund-Katz; Michael C Phillips; Hiroyuki Saito
Journal:  Biochim Biophys Acta       Date:  2010-10-30

4.  Influence of apolipoprotein (Apo) A-I structure on nascent high density lipoprotein (HDL) particle size distribution.

Authors:  Charulatha Vedhachalam; Palaniappan Sevugan Chetty; Margaret Nickel; Padmaja Dhanasekaran; Sissel Lund-Katz; George H Rothblat; Michael C Phillips
Journal:  J Biol Chem       Date:  2010-08-02       Impact factor: 5.157

Review 5.  High-density lipoprotein heterogeneity and function in reverse cholesterol transport.

Authors:  George H Rothblat; Michael C Phillips
Journal:  Curr Opin Lipidol       Date:  2010-06       Impact factor: 4.776

Review 6.  High density lipoprotein structure-function and role in reverse cholesterol transport.

Authors:  Sissel Lund-Katz; Michael C Phillips
Journal:  Subcell Biochem       Date:  2010

7.  Aromatic residues in the C-terminal helix of human apoC-I mediate phospholipid interactions and particle morphology.

Authors:  Patrick F James; Con Dogovski; Renwick C J Dobson; Michael F Bailey; Kenneth N Goldie; John A Karas; Denis B Scanlon; Richard A J O'Hair; Matthew A Perugini
Journal:  J Lipid Res       Date:  2008-11-04       Impact factor: 5.922

8.  Structural and functional consequences of the Milano mutation (R173C) in human apolipoprotein A-I.

Authors:  Eric T Alexander; Masafumi Tanaka; Momoe Kono; Hiroyuki Saito; Daniel J Rader; Michael C Phillips
Journal:  J Lipid Res       Date:  2009-03-24       Impact factor: 5.922

Review 9.  Update on strategies to increase HDL quantity and function.

Authors:  Danielle Duffy; Daniel J Rader
Journal:  Nat Rev Cardiol       Date:  2009-06-02       Impact factor: 32.419

10.  Oxidation of apolipoprotein A-I by myeloperoxidase impairs the initial interactions with ABCA1 required for signaling and cholesterol export.

Authors:  Baohai Shao; Chongren Tang; Jay W Heinecke; John F Oram
Journal:  J Lipid Res       Date:  2010-01-11       Impact factor: 5.922

View more
  18 in total

Review 1.  Genetics of cholesterol efflux.

Authors:  Iulia Iatan; Aurélien Palmyre; Sarah Alrasheed; Isabelle Ruel; Jacques Genest
Journal:  Curr Atheroscler Rep       Date:  2012-06       Impact factor: 5.113

2.  The roles of C-terminal helices of human apolipoprotein A-I in formation of high-density lipoprotein particles.

Authors:  Kohjiro Nagao; Mami Hata; Kento Tanaka; Yuki Takechi; David Nguyen; Padmaja Dhanasekaran; Sissel Lund-Katz; Michael C Phillips; Hiroyuki Saito
Journal:  Biochim Biophys Acta       Date:  2013-10-09

Review 3.  Is ABCA1 a lipid transfer protein?

Authors:  Michael C Phillips
Journal:  J Lipid Res       Date:  2018-01-05       Impact factor: 5.922

Review 4.  Lipid-free Apolipoprotein A-I Structure: Insights into HDL Formation and Atherosclerosis Development.

Authors:  Xiaohu Mei; David Atkinson
Journal:  Arch Med Res       Date:  2015-06-03       Impact factor: 2.235

5.  Significance of the hydrophobic residues 225-230 of apoA-I for the biogenesis of HDL.

Authors:  Panagiotis Fotakis; Ioanna Tiniakou; Andreas K Kateifides; Christina Gkolfinopoulou; Angeliki Chroni; Efstratios Stratikos; Vassilis I Zannis; Dimitris Kardassis
Journal:  J Lipid Res       Date:  2013-10-12       Impact factor: 5.922

6.  Apolipoprotein C-I binds more strongly to phospholipid/triolein/water than triolein/water interfaces: a possible model for inhibiting cholesterol ester transfer protein activity and triacylglycerol-rich lipoprotein uptake.

Authors:  Nathan L Meyers; Libo Wang; Donald M Small
Journal:  Biochemistry       Date:  2012-02-02       Impact factor: 3.162

7.  Expression of the C-terminal domain of human apolipoprotein A-I using a chimeric apolipoprotein.

Authors:  Daniel E Sallee; James V C Horn; Lukas A Fuentes; Paul M M Weers
Journal:  Protein Expr Purif       Date:  2017-06-15       Impact factor: 1.650

Review 8.  Amyloid-Forming Properties of Human Apolipoproteins: Sequence Analyses and Structural Insights.

Authors:  Madhurima Das; Olga Gursky
Journal:  Adv Exp Med Biol       Date:  2015       Impact factor: 2.622

9.  Transfer of C-terminal residues of human apolipoprotein A-I to insect apolipophorin III creates a two-domain chimeric protein with enhanced lipid binding activity.

Authors:  James V C Horn; Rachel A Ellena; Jesse J Tran; Wendy H J Beck; Vasanthy Narayanaswami; Paul M M Weers
Journal:  Biochim Biophys Acta Biomembr       Date:  2017-04-21       Impact factor: 3.747

Review 10.  ApoA1 and ApoA1-specific self-antibodies in cardiovascular disease.

Authors:  Dimitry A Chistiakov; Alexander N Orekhov; Yuri V Bobryshev
Journal:  Lab Invest       Date:  2016-05-16       Impact factor: 5.662

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.